 Home > Biochemistry News > Biotechnology News > Blueprint Announces Strategic Collaboration with Proteovant to Develop Targeted Protein Degradation Therapies

Blueprint Announces Strategic Collaboration with Proteovant to Develop Targeted Protein Degradation Therapies

 Last Update: 2022-05-23
 Source: Internet
 Author: User

Tags

emetrol medicine

bdnf protein

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On February 28, 2022, Blueprint Medicines announced a strategic collaboration with Proteovant Therapeutics, a Roivant Sciences company, to discover and develop novel targeted protein degradation therapies aimed at addressing unmet medical needs in cancer and hematological diseases

Proteovant harnesses the protein degradation process to discover and develop transformative medicines, aided by cutting-edge computational tools such as artificial intelligence (AI) and advanced machine learning models

The collaboration will combine Proteovant's AI-based Targeted Protein Degradation (TPD) technology platform with Blueprint Medicine's expertise in precision medicine to discover novel targeted protein degradation agents

Under the terms of the agreement, Proteovant will receive an upfront payment of $20 million and will be eligible to receive up to an additional $632 million in potential research, development, regulatory and commercialization milestone payments, as well as tiered licenses for future net product sales from the first two programs royalties

References:

[1] Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies.

(Original abridged)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.